Center of Non-Infectious Liver Diseases, Peking University 302 Clinical Medical School, Beijing, China.
Center of Non-Infectious Liver Diseases, Beijing 302 Hospital, Beijing, China.
Mediators Inflamm. 2017;2017:5314213. doi: 10.1155/2017/5314213. Epub 2017 Oct 18.
The new member of the IL-1 family, interleukin-33 (IL-33), participates in the progression of a variety of diseases through binding with its receptor ST2. Recently, much clinical evidence and experimental data have indicated that IL-33 is associated with various liver diseases. This review primarily addresses the relationship between IL-33 and several hepatic diseases. IL-33 can alleviate high-fat diet- (HFD-) induced hepatic steatosis and insulin resistance, and IL-33 acts as an alarmin, which quickly triggers the immune system to respond to virus invasion and toxic damage to the liver. However, when liver injury is chronic, IL-33 promotes Th2 reactions and hepatic stellate cell (HSC) activity, facilitating progression to liver fibrosis. The complicated functions of IL-33 should be considered before its clinical application.
白细胞介素-33（IL-33）是白介素-1 家族的新成员，通过与其受体 ST2 结合参与多种疾病的进展。最近，大量的临床证据和实验数据表明，IL-33与各种肝脏疾病有关。本综述主要探讨了 IL-33 与几种肝疾病的关系。IL-33 可减轻高脂饮食（HFD）诱导的肝脂肪变性和胰岛素抵抗，并且 IL-33 作为警报素，可迅速触发免疫系统对病毒入侵和肝毒性损伤做出反应。然而，当肝损伤为慢性时，IL-33 促进 Th2 反应和肝星状细胞（HSC）活性，促进肝纤维化进展。在 IL-33 的临床应用之前，应该考虑其复杂的功能。
